title: Bosentan enters market with risk management program.
authors.forename: Cheryl A
authors.initials: CA
authors.lastname: Thompson
mesh_terms: D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000077300:Bosentan; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004345:Drug Industry; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D008111:Liver Function Tests; D011258:Pregnancy Tests; D011358:Product Surveillance, Postmarketing; D012308:Risk Management; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000959:Antihypertensive Agents; D013449:Sulfonamides; D000077300:Bosentan